Aaron Bloomer - 23 Dec 2025 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Reporting relationship: EVP, Chief Financial Officer
Issuer ticker: EXAS
Reported as of: 23 Dec 2025
Net transaction value: -$2,846,276
SEC form: 4
Accepted by SEC: 30 Dec 2025, 16:30:03 UTC
Prior SEC filing: 17 Apr 2025
Next SEC filing: 27 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Aaron Bloomer by Mark Busch, attorney-in- fact

Key filing fact

Aaron Bloomer filed Form 4 for EXACT SCIENCES CORP (EXAS) on 30 Dec 2025.

Key facts

This page summarizes Aaron Bloomer's Form 4 filing for EXACT SCIENCES CORP (EXAS).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 30 Dec 2025, 16:30.

Change

Previous filing in this sequence was filed on 17 Apr 2025.
Current net transaction value: -$2,846,276.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002019003 Primary reporting owner

Bloomer Aaron

Relationship: EVP, Chief Financial Officer
Address: C/O EXACT SCIENCES CORP, 5505 ENDEAVOR LANE, MADISON
Signature: /s/ Aaron Bloomer by Mark Busch, attorney-in- fact
Signature date: 30 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EXAS transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +38,715
Change %: +284%
Price: $0.000000
Shares after: 52,338
Date: 23 Dec 2025
Ownership: Direct
Footnotes: F1

EXAS transaction

Common Stock

Tax liability

Transaction value: $1,746,315
Shares: -17,151
Change %: -33%
Price: $101.82
Shares after: 35,187
Date: 23 Dec 2025
Ownership: Direct
Footnotes: F2

EXAS transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +24,384
Change %: +69%
Price: $0.000000
Shares after: 59,571
Date: 23 Dec 2025
Ownership: Direct
Footnotes: F1

EXAS transaction

Common Stock

Tax liability

Transaction value: $1,099,961
Shares: -10,803
Change %: -18%
Price: $101.82
Shares after: 48,768
Date: 23 Dec 2025
Ownership: Direct
Footnotes: F2, F3

EXAS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 212
Date: 23 Dec 2025
Ownership: Held in 401(k) Plan

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EXAS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -38,715
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 23 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,715
Exercise price
Footnotes: F4, F5

EXAS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -24,384
Change %: -85%
Price: $0.000000
Shares after: 4,395
Date: 23 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,384
Exercise price
Footnotes: F4, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents shares of common stock received upon vesting of a restricted stock unit award.

Footnote F2

Represents shares of Common Stock retained by Exact Sciences Corporation (the "Issuer") for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units.

Footnote F3

In addition to the shares of Common Stock reported on this Form 4, which total 48,980 shares, Mr. Bloomer also holds, in the aggregate, an additional 4,395 unvested restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock

Footnote F4

Each restricted stock unit represents a contingent right to receive one share of common stock.

Footnote F5

This award was scheduled to vest in three equal installments on April 15, 2026, April 15, 2027, and April 15, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.

Footnote F6

This award was scheduled to vest in four equal installments on February 27, 2026, February 26, 2027, February 29, 2028, and February 28, 2029, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation.